FBIO

Fortress is a holding company that incubates drug assets across publicly-traded and private subsidiaries (Journey/DERM, Mustang, Avenue, Cyprium, etc.), and the headline FY2025 'profit' of $6.82M is misleading. Operating income was -$70.2M (operating margin -111%) and operating cash flow was -$65.8M; the swing to positive net income came from non-operating items tied to subsidiary monetizations (Checkpoint acquired by Sun Pharma in May 2025, Baergic by Axsome in November 2025), and diluted EPS was still -$0.07. Revenue of $63.3M (+9.7%) is real but choppy — it fell from an $84.5M peak in FY2023 to $57.7M in FY2024 before recovering — and is essentially Journey's commercial dermatology portfolio ($61.2M). This is a structurally unprofitable operating model with a -$734M accumulated deficit.

The balance sheet looks adequate on the surface (equity $49.9M, cash $79.4M, current assets $124M vs $49.7M current liabilities), but the ~$66M annual operating burn implies roughly a year of runway absent financing, and the filing flags real financing distress: the board paused Series A preferred dividends in July 2024, which cost the company Form S-3 eligibility and access to its $42.1M shelf under the baby-shelf rules. Funding has come through dilutive ATM issuance (shares +12.4% YoY, Fortress and Journey both selling stock), so common holders face ongoing dilution on top of $52.4M long-term debt and 2.47x liabilities/equity.